New Formulations Will Speed Discovery of Biomarkers and Precision Therapies MINNEAPOLIS , Feb. 05, 2020 (GLOBE NEWSWIRE) -- TumorGenesis, Inc. a subsidiary of Predictive Oncology, Inc. (NASDAQ: POAI) has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor

AI platform was developed at the Ray and Stephanie Lane Center for Computational Biology, which became the Computational Biology Department at Carnegie Mellon University and was successfully tested by several pharma companies MINNEAPOLIS , Jan. 24, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.

MINNEAPOLIS , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for

MINNEAPOLIS , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for

MINNEAPOLIS , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for

MINNEAPOLIS , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.  (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has received indications of interest from

MINNEAPOLIS , Nov. 25, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that based on a notification letter (the “Notification

MINNEAPOLIS , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.  (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it entered into a $15 million common stock purchase

NEW YORK , Nov. 19, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery, today announces the broadcast of its

MINNEAPOLIS , Nov. 15, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through